Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial

Abstract Background The treatments for refractory leptomeningeal metastasis (RLM) of non-small cell lung cancer (NSCLC) are limited, and response assessment is complex and challenging. This clinical trial aimed to evaluate the efficacy of intrathecal pemetrexed (IP) and response assessment using cer...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	BMC Medicine
المؤلفون الرئيسيون:	Qingsheng Xu, Kaiyuan Huang, Luqing Tong, Danfang Yan, Yilei Zhao, Hanjin Yang, Weili Jin, Luyuan Zhang, Jinquan Cai, Qun Chen
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2025-05-01
الموضوعات:	Intrathecal pemetrexed Response assessment Tumor marker in cerebrospinal fluid Refractory leptomeningeal metastasis Non-small-cell lung cancer
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12916-025-04134-7